top of page
.jpg)
Search
Groundbreaking Research from UPMC Highlights Opioids’ Suppressive Impact on Immune Checkpoint Inhibitors and the Potential of Axelopran, an Opioid Antagonist to Reverse It
San Francisco, CA – December 04, 2024 – Glycyx, a clinical-stage biopharmaceutical company advancing axelopran, a novel solution to...
Dec 4, 2024
bottom of page